Perspective Therapeutics (NYSEAMERICAN:CATX) Hits New 52-Week High at $1.87

Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) hit a new 52-week high during trading on Thursday . The company traded as high as 1.87 and last traded at 1.80, with a volume of 1132979 shares trading hands. The stock had previously closed at 1.70.

Analyst Ratings Changes

CATX has been the topic of several recent analyst reports. B. Riley lifted their price objective on shares of Perspective Therapeutics from $1.20 to $1.70 and gave the stock a “buy” rating in a research note on Tuesday, April 9th. Oppenheimer reiterated an “outperform” rating and issued a $1.50 target price (up from $1.20) on shares of Perspective Therapeutics in a report on Monday, April 1st.

Perspective Therapeutics Trading Up 4.6 %

The company has a quick ratio of 1.07, a current ratio of 1.07 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $1.06 billion, a P/E ratio of -18.10 and a beta of 1.43.

Insiders Place Their Bets

In related news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The shares were acquired at an average cost of 0.95 per share, with a total value of 57,409,487.05. Following the transaction, the insider now owns 116,773,394 shares of the company’s stock, valued at approximately 110,934,724.30. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 3.52% of the company’s stock.

Institutional Investors Weigh In On Perspective Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. ZWJ Investment Counsel Inc. acquired a new stake in Perspective Therapeutics in the 1st quarter valued at $26,000. Simplicity Wealth LLC bought a new position in shares of Perspective Therapeutics in the 1st quarter valued at about $40,000. Bank of New York Mellon Corp acquired a new stake in shares of Perspective Therapeutics in the third quarter valued at about $42,000. RIA Advisory Group LLC boosted its position in Perspective Therapeutics by 1,313.4% during the first quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock valued at $127,000 after purchasing an additional 99,293 shares during the last quarter. Finally, Taylor & Morgan Wealth Management LLC grew its stake in Perspective Therapeutics by 8.7% in the fourth quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company’s stock valued at $251,000 after purchasing an additional 50,000 shares in the last quarter. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.